Four-in-10 U.S. adults are expected to develop Type 2 diabetes at some point in their lifetime, according to a new study published in The Lancet Diabetes & Endocrinology in August, suggesting that as many as 126 million consumers will be looking for treatment options, including self-monitoring their condition at home.
SpermCheck in August gained additional retail distribution for its SpermCheck Fertility, an FDA-approved at-home screening test that determines with 98% accuracy whether a man has a normal or low sperm count. Infertility affects nearly 7 million U.S. couples every year.
The American Heart Association’s journal Hypertension this summer plugged home blood-pressure monitoring kits, noting that the self-care diagnostics can save insurance companies money by improving healthcare quality and reducing healthcare costs — both buzz words in the changing healthcare paradigm that places a greater emphasis on preventive health care.
Last year, Drug Store Newscovered extensively the results from Thrifty White's successful medication synchronization program. DSN recently checked in with Tim Weippert, Thrifty White EVP pharmacy, to get an update.
Thirty years ago, Democratic and Republican members of Congress hammered out a rare and prescient bipartisan compromise bill that transformed the pharmaceutical landscape forever and unleashed the modern generic drug industry. That law, known as the Hatch-Waxman Act, has proven to be one of the most far-reaching and impactful pieces of legislation ever to shape the American healthcare system.